Dr. Santiago Aparo, MD

Dr. Aparo practices at Baptist Health Baptist Hospital in Miami, Florida, part of Baptist Health South Florida.

Dr. Aparo's NPI, 1407172497, was assigned on April 15, 2010. Dr. Aparo graduated from Univ Salvador- Fac Med in 2002. Dr. Aparo holds Florida license ME 120595.

Dr. Aparo's primary practice is Baptist Health Baptist Hospital, at 8900 N Kendall Dr, Miami, FL 33176 in Miami-Dade County. The practice phone is (786) 596-1960.

Dr. Aparo's primary practice is Baptist Health Baptist Hospital in Miami, Florida, part of Baptist Health South Florida. Dr. Aparo is also affiliated with South Miami Hospital. The medical group on file is Baptist Health Medical Group Oncology. Dmand AI also links Dr. Aparo to 3 more hospitals and 1 breast imaging center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Aparo practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Aparo's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Aparo is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Aparo's licenses on file in 2 states: Florida and New York.

Dmand AI lists breast cancer, chronic anemia, chronic embolism thrombosis, colorectal cancer, deep vein thrombosis (DVT), immune deficiency disease, lung cancer and neutropenia among the conditions Dr. Aparo treats.

CMS data shows 1,177 Medicare services from Dr. Aparo across 11 procedure codes in 2024, for 398 Medicare patients. Medicare paid $67,014 for them.

CMS counts 398 Medicare patients who saw Dr. Aparo in 2024. The largest group is 65 to 74, with 144 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 29% are also on Medicaid. Their average risk score is 2.35, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Aparo's median patient age at 68, with 55% women.

In 2024, Dr. Aparo wrote 391 Medicare Part D claims for 116 patients. 74% of them were for generic drugs. CMS names the drug for 244 of them, across 8 drugs with 11 or more claims each, at $267,507 in total drug cost. In 2023, CMS named 129 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Aparo for performance year 2024, reported as part of a group. Dr. Aparo accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Aparo as offering telehealth.

Dmand AI links 22 papers to Dr. Aparo, published from 2011 to 2025. 2018 was the busiest year, with 4. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Pancreatic Neoplasms and Adenocarcinoma. Dr. Aparo has published most often in Cancer Control. Dr. Aparo's most frequent co-authors are Jennifer W. Chuy, MD, Horacio J. Asbun, MD and Imran N. Chaudhary, MD.

Dmand AI links Dr. Aparo to 3 clinical trials. 1 is still active or recruiting. Conditions studied include Pancreatic Neoplasms, Gastrointestinal Stromal Tumors and Pancreatic cancer, adult.

CMS Open Payments shows 91 general payments to Dr. Aparo from 29 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 60% of the total. BioNTech SE paid the most, $3,625.

Dr. Aparo graduated from Univ Salvador- Fac Med in 2002. Dr. Aparo is a member of ASCO.

Dr. Aparo is in network with 13 carriers, including Aetna, Excellus BlueCross BlueShield and Elevance. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.